hastango.blogg.se

Patients were randomly assigned (1:1) to receive afatinib (40 mg per day) or erlotinib (150 mg per day) until disease progression. Eligible patients had stage IIIB or IV lung SCC and had progressed after at least four cycles of platinum-based chemotherapy. LUX-Lung 8 ( NCT01523587) enroled patients between March 2012 and January 2014 in 183 cancer centres located in 23 countries worldwide and this final analysis had a data cut-off of March 2018. We report the final overall survival (OS) and safety analyses of LUX-Lung 8 and investigate the characteristics of patients who achieved long-term benefit (≥12 months' treatment).

LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib and erlotinib as second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the lung. 14 Vall d'Hebron University Hospital and Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain.13 Boehringer Ingelheim International GmbH, Ingelheim 55216, Germany.12 Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA.10 Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.9 Istituto Nazionale Tumori - IRCCS "Fondazione G.8 Hospital Lozano Blesa, Zaragoza, Spain.7 Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece.

6 Ege University Faculty of Medicine, Izmir, Turkey.5 Chungbuk National University College of Medicine, Cheongju, South Korea.4 National & Kapodistrian University of Athens, Athens, Greece.3 Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.2 Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain.1 The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 8L6, Canada.